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A B S T R A C T   
Introduction: Compared to surgery there is no evidence on bronchoscopic lung volume reduction (LVR) in patients 
with fading benefit after LVR surgery. CASE REPORT: We present a case of 64-year old female patient who was 
successfully treated with bronchial thermal vapor ablation (BTVA) after previous ineffective lung volume 
reduction (LVR) surgery several months earlier. CONCLUSIONS: Bronchoscopic LVR, in particular BTVA, might 
be considered in patients with fading or missing effects after previous LVRS. At least, the safety profile of BTVA 
seems not be adversely affected by previous LVRS, when proper patient selection and procedure planning are 
ensured.   
1. Introduction 
Pulmonary function, dyspnea and quality of life have been shown to 
improve significantly after both surgical and bronchoscopic LVR in pa-
tients with severe emphysema and hyperinflation [1]. However, since 
chronic obstructive pulmonary disease (COPD) is a progressive disorder, 
the beneficial effects of all LVR procedures are only temporary and 
symptoms return to baseline levels after months to years [2–4]. Thus, 
neither lung volume reduction (LVR) procedure is able to alter the 
natural course of COPD with annual decline of pulmonary function and 
again increasing hyperinflation [5]. Unfortunately, only few COPD pa-
tients qualify for lung transplantation due to advanced age and 
co-morbidities. Attempts of repeated LVR surgery (Re-LVRS) have been 
published with promising results in highly selected patients, who 
increasingly deteriorate after initially successful LVRS [6,7]. Compared 
to surgery there is no evidence on bronchoscopic LVR in patients who 
had previous LVRS. Concerning BTVA, there is evidence on successful 
segmental treatment with acceptable safety profile in emphysema pa-
tients, who did not have a previous LVR [8]. To the best of our knowl-
edge, this is the first report on a successful bronchoscopic LVR using 
BTVA after previous LVRS. 
2. Case report 
A 64-year old female patient was referred for evaluation of 
increasing dyspnea five months after bilateral thoracoscopic LVRS in her 
upper lobes. Immediately after LVRS she had noticed some improvement 
of her dyspnea, but this continued only for three months. Since then, her 
symptoms slowly returned to baseline. Compared to preoperative 
values, her FEV1 had slightly decreased, and residual volume (RV) had 
increased by 220 ml (Table 1). According to her recent body-
plethysmography with RV of 5.08 l (295% predicted) and RV/total lung 
capacity (TLC) of 0.77, symptomatic hyperinflation was suspected. Her 
drug treatment included inhalative tiotropium and fluticasone/salme-
terol, and theophylline 1 � 200mg orally, which was unchanged to 
preoperative. Inhalation technique was checked and found to be accu-
rate. Other causes of increasing dyspnea (e.g. congestive heart failure, 
pulmonary embolism, and pleural effusion) were excluded by computed 
tomography (CT) and echocardiography. Pulmonary hypertension 
seemed not causative for her symptoms, since peak systolic right ven-
tricular pressure on echocardiography had decreased from 34 mmHg 
preoperatively to 31 mmHg. 6-minute walking distance (6-MWD) was 
280 m, which was 70 m more compared to the preoperative value. 
Quantitative CT analysis using the software by Intervapor® (Uptake 
Medical® Technology Inc., Seattle WA, USA) revealed a slightly het-
erogeneous emphysema with interlobar fissure completeness between 
69 and 92%. Due to upper lobe disease severity (proportion of voxels 
with density less than  950 HU) of 44% in LB1/2 with a heterogeneity 
index of 1.2 between segment and ipsilateral lobe, and an estimated 
target volume of 233 ml, bronchoscopic LVR using bronchial thermal 
vapor ablation (BTVA) was a possible treatment option, since the patient 
refused to undergo re-LVRS. Seven months after unsuccessful LVR sur-
gery, LB1/2 was treated with BTVA in general anesthesia. Vapor was 
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delivered during 7.2 seconds corresponding to 8.5 cal/g lung tissue 
using a segmentally wedged and properly positioned balloon catheter 
(InterVapor®) according to a recent best practice recommendation 
paper [9]. The patient tolerated BTVA treatment without any complaints 
and was discharged on the following day. Prophylactic medication with 
prednisone 20mg/d and amoxicillin-clavulanate (625mg tid) was given 
for seven days. At follow-up examinations six weeks and six months after 
BTVA, the patient refused any side effects like increased cough, fever, 
chills, or hemoptysis. However, her dyspnea already improved after six 
weeks persisting for at least six months, and 6-MWD increased to 325 
and 420 m after six weeks and six months, respectively. Also, pulmonary 
function values improved impressively (Table 1). On CT follow-up after 
six months, there was evidence of new symmetric bilateral consolida-
tions imitating round atelectasis in both lower lobes and faint reticular 
changes in LB1/1 (Figs. 1–2). 
BTVA, bronchial thermal vapor ablation; FEV1, forced expiratory 
volume in 1 s; FVC, forced vital capacity; LVR, lung volume reduction; 
RV, residual volume; TLC, total lung capacity; TLCO, transfer factor of 
the lung for carbon monoxide; 6-MWD, 6 min walking distance. 
3. Discussion 
Recurrent hyperinflation with deterioration of dyspnea and quality 
of life several months to years after LVR is not unusual. The beneficial 
effects on FEV1, hyperinflation and dyspnea after LVRS were persistent 
for up to three years in both homogeneous and heterogeneous emphy-
sema [10]. Similar long-term results were found after bronchoscopic 
LVR using endobronchial valves with maintained success for up to five 
years [11], and after LVR coils with declining benefits after three years 
[3]. Since BTVA is a relatively new LVR technique, there are only 
12-month efficacy and safety data available [12]. Retrospective data on 
Re-LVR after deteriorating effects after a previous successful LVRS are 
only available for surgery, showing improvements of dyspnea and lung 
function for up to one year [7]. In this publication, there was usually a 
period of maintained success between initial LVRS and Re-LVRS of five 
years. However, the situation is different in the presented case, since the 
patient had never shown any benefit after LVRS, and the period between 
LVRS and Re-LVR was only six months. Therefore, the presented case is a 
non-responder after LVRS rather than secondary decliner. 
Analogously to the STEP-UP trial, a target energy dose of 8.5 calories 
per gram of lung tissue was delivered [8,12]. The choice of the dose is 
the result of several previous studies with different vapor doses ranging 
between 5 and 10 cal/g [9]. The dose chosen in the presented patient is a 
trade-off between optimal benefit and acceptable risk, since adverse 
events (e.g. pneumonitis) are associated with the volume of the treated 
lobe [13]. Therefore, segmental (sequential) rather than lobar vapor 
treatment is recommended [9]. However, in our patient, the second 
BTVA treatment was withheld due to the successful first application. 
Despite the ongoing favorable outcome of BTVA after previous LVRS, 
the mechanism is not obvious in the presented case. In particular, the 
cause and effect of the new bilateral consolidations in both lower lobes, 
where neither LVRS nor BTVA had been performed, remain unex-
plained. Compared to this finding, the BTVA target zone in LB1/2 
showed relatively faint reticular changes. In addition, it is unusual that 
patients treated with BTVA show improved pulmonary function and 
dyspnea after only six weeks, since vapor-induced inflammation and 
scarring may take several months. Possibly, there was an alternative, 
List of abbreviations 
BTVA bronchial thermal vapor ablation 
COPD chronic obstructive pulmonary disease 
FEV1 forced expiratory volume in first second 
LVR lung volume reduction 
LVRS lung volume reduction surgery 
6MWD 6-min walking distance 
RV residual volume 
TLC total lung capacity  
Table 1 
Pulmonary function tests and 6-min walking distance.   
Pre-LVR 
surgery 







FVC, liters (% 
predicted) 
1.60 (78) 1.52 (74) 2.06 (83) 2.23 (110) 
FEV1, liters (% 
predicted) 
0.68 (40) 0.65 (39) 0.97 (50) 1.10 (66) 
FEV1/FVC 0.38 0.42 0.47 0.48 
TLC, liters (% 
predicted) 
6.63 (164) 6.62 (164) 4.75 (117) 4.90 (121) 
RV, liters (% 
predicted) 
4.86 (282) 5.08 (295) 2.57 (148) 2.62 (151) 
RV/TLC 0.73 0.77 0.54 0.54 
TLCO, % 
predicted 
20 20 34 30 
6-MWD, meters 210 280 325 420  
Fig. 1. Chest computed tomography after LVRS and BTVA (upper lobes).  
Fig. 2. Chest computed tomography after LVRS and BTVA (lower lobes).  
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unknown mechanism, which eventually led to the favorable outcome. 
4. Conclusion 
Bronchoscopic LVR, in particular BTVA, might be considered in pa-
tients with fading effects after previous successful LVRS. At least, the 
safety profile of BTVA seems not be adversely affected by previous LVRS, 
when proper patient selection and procedure planning are ensured. 
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Fig. 1 show representative transverse sections in prone position of 
upper lobes 6 months after BTVA and 12 months after initial LVRS, 
respectively. In the upper left lobe (LB1/2), there are faint reticular 
changes, which might be attributable to scarring after LVRS or BTVA. 
Fig. 2 show representative transverse sections in prone position of 
lower lobes 6 months after BTVA and 12 months after initial LVRS, 
respectively. In both lower lobes, where neither LVRS nor BTVA had 
been performed, there are symmetrical consolidations of unknown cause 
imitating round atelectasis. 
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